BEAM•benzinga•
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
Summary
Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 10, 2025 by benzinga